Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?
Abstract
Aim: We investigate the concordance, in terms of favoring the same treatment arm, between clinician-reported symptomatic adverse events (AEs) and information obtained via patient-reported outcomes (PRO) measures in cancer randomized controlled trials (RCTs). Methods: We conducted a systematic literature search to identify all RCTs conducted in breast, colorectal, lung and prostate cancer, published between 2004 and 2017. Results: We identified 207 RCTs. In the majority of RCTs (n=133, 64.2%) a discordance between PROs and AEs was found. In 104 studies (50.2%), PRO data favored the experimental arm when AEs did not, while the opposite situation was found in 29 trials (14.0%). Conclusion: Frequently, information obtained via PRO measures and clinician-reported AEs do not favor the same treatment arm in RCT settings.
Supplementary Material
File (suppl_file.docx)
- Download
- 24.09 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Stickel A, Goerling U. Quality of life in oncology. Recent Results Cancer Res. 210, 163–180 (2018).
2.
Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat. Rev. Clin. Oncol. 9(2), 98–109 (2011).
3.
Basch E, Dueck AC, Rogak LJ et al. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials. JAMA Oncol. 3(8), 1043–1050 (2017).
4.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (2018). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5×11.pdf.
5.
Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 22(17), 3485–3490 (2004).
6.
Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am. J. Manag. Care 14(8), 530–539 (2008).
7.
Basch E, Iasonos A, Mcdonough T et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 7(11), 903–909 (2006).
8.
Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat. Rev. Clin. Oncol. 13(5), 319–325 (2016).
•• Provides description of the barriers and challenges that should be addressed when considering integration of patient-reported outcomes (PRO) toxicity monitoring in oncology clinical trials.
9.
Efficace F, Rosti G, Aaronson N et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99(4), 788–793 (2014).
10.
Basch E, Reeve BB, Mitchell SA et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl Cancer Inst. 106(9), (2014).
•• Describes development of the patient reported outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE).
11.
Efficace F, Fayers P, Pusic A et al. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer 121(18), 3335–3342 (2015).
• Evaluates the completeness of PRO reporting according to the Consolidated Standards of Reporting Trials (CONSORT) PRO extension.
12.
Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann. Oncol. 18(4), 775–781 (2007).
13.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
14.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
15.
Efficace F, Feuerstein M, Fayers P et al. Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur. Urol. 66(3), 416–427 (2014).
16.
Efficace F, Jacobs M, Pusic A et al. Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making. Eur. J. Cancer 50(11), 1925–1941 (2014).
17.
NCI-PRO-CTCAE Items-English. Item Library Version 1.0 (2018). https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_english.pdf.
18.
Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365–376 (1993).
19.
Di Maio M, Gallo C, Leighl NB et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J. Clin. Oncol. 33(8), 910–915 (2015).
•• Compares reporting by patients and physicians of six toxicities within three randomized trials.
20.
Reilly CM, Bruner DW, Mitchell SA et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support. Care Cancer 21(6), 1525–1550 (2013).
21.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006–1012 (2009).
22.
Schuurhuizen C, Braamse AMJ, Konings I et al. Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. Ann. Oncol. 28(3), 478–486 (2017).
• Reviews whether severe toxicity affects global quality of life in patients with metastatic colorectal cancer receiving palliative systemic treatment.
23.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47(1), 207–214 (1981).
24.
Basch E, Jia X, Heller G et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J. Natl Cancer Inst. 101(23), 1624–1632 (2009).
25.
Atkinson TM, Ryan SJ, Bennett AV et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support. Care Cancer 24(8), 3669–3676 (2016).
26.
Quinten C, Maringwa J, Gotay CC et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J. Natl Cancer Inst. 103(24), 1851–1858 (2011).
27.
Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 36(6), E1–E16 (2013).
28.
Gilbert A, Ziegler L, Martland M et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. Int. J. Radiat. Oncol. Biol. Phys. 92(3), 555–567 (2015).
29.
Brundage M, Bass B, Davidson J et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual. Life Res. 20(5), 653–664 (2011).
30.
Reeve BB, Mitchell SA, Dueck AC et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J. Natl Cancer Inst. 106(7), (2014).
31.
Kluetz PG, Slagle A, Papadopoulos EJ et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin. Cancer Res. 22(7), 1553–1558 (2016).
Information & Authors
Information
Published In
Copyright
© 2019 Future Medicine Ltd.
History
Received: 7 September 2018
Accepted: 11 January 2019
Published online: 6 March 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0092
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Mayuri Charnalia, Nilesh Ranjan, Sofia Spampinato, Remi Nout, Richard Pötter, Astrid De Leeuw, Kathrin Kirchheiner, Kari Tanderup, Supriya Chopra, Cumulative gastrointestinal adverse events in EMBRACE-I: comparative evaluation of CTCAE vs. MOSES methods in predicting the impact of incident vs. persistent adverse events on quality of life, Radiotherapy and Oncology, 10.1016/j.radonc.2026.111489, 219, (111489), (2026).
- Defa Zhang, Yali Wang, Qian Wang, Huiqing Mao, Miaomiao Zhang, Ping Xu, Shuo Guo, Rong Yan, Psychometric properties of patient-reported outcome measures for symptom assessment in patients with cancer receiving immunotherapy: A systematic review following the COSMIN 2.0 guidelines, Asia-Pacific Journal of Oncology Nursing, 10.1016/j.apjon.2025.100774, 12, (100774), (2025).
- S. Huynh-Dagher, T.-A. Duong, C. Tournigand, E. Kempf, G. Lamé, Concordance between patient-reported outcomes and CTCAE clinician-reported toxicities during outpatient chemotherapy courses: a retrospective cohort study in routine care, ESMO Real World Data and Digital Oncology, 10.1016/j.esmorw.2025.100127, 8, (100127), (2025).
- Minna Grahvendy, Bena Brown, Laurelie R. Wishart, A Pilot Study on the Collection of Adverse Event Data from the Patient Using an Electronic Platform in a Cancer Clinical Trial Unit, Drugs - Real World Outcomes, 10.1007/s40801-024-00461-y, 11, 4, (725-734), (2024).
- Minna Grahvendy, Bena Brown, Laurelie R. Wishart, Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review, The Patient - Patient-Centered Outcomes Research, 10.1007/s40271-024-00689-4, 17, 4, (335-347), (2024).
- K Sjövall, U Langegård, P Fransson, E Nevo-Ohlsson, I Kristensen, K Ahlberg, B Johansson, Evaluating patient reported outcomes and experiences in a novel proton beam clinic – challenges, activities, and outcomes of the ProtonCare project, BMC Cancer, 10.1186/s12885-023-10586-y, 23, 1, (2023).
- Beate Bestmann, Thomas Küchler, Lebensqualität in der Uroonkologie, Uroonkologie, 10.1007/978-3-662-54652-9_2-1, (1-9), (2022).
- Fabio Efficace, Andrea Patriarca, Mario Luppi, Leonardo Potenza, Giovanni Caocci, Agostino Tafuri, Francesca Fazio, Claudio Cartoni, Maria Teresa Petrucci, Ida Carmosino, Riccardo Moia, Gloria Margiotta Casaluci, Paola Boggione, Elisabetta Colaci, Davide Giusti, Valeria Pioli, Francesco Sparano, Francesco Cottone, Paolo De Fabritiis, Nicolina Rita Ardu, Pasquale Niscola, Isabella Capodanno, Anna Paola Leporace, Sabrina Pelliccia, Elisabetta Lugli, Edoardo La Sala, Luigi Rigacci, Michelina Santopietro, Claudio Fozza, Sergio Siragusa, Massimo Breccia, Paola Fazi, Marco Vignetti, Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform, Frontiers in Oncology, 10.3389/fonc.2022.826040, 12, (2022).
- Lun Li, Benlong Yang, Hongyuan Li, Jian Yin, Feng Jin, Siyuan Han, Ning Liao, Jingping Shi, Rui Ling, Zan Li, Lizhi Ouyang, Xiang Wang, Peifen Fu, Zhong Ouyang, Binlin Ma, Xinhong Wu, Haibo Wang, Jian Liu, Zhimin Shao, Jiong Wu, Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol, BMJ Open, 10.1136/bmjopen-2019-032945, 9, 12, (e032945), (2019).